<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02893215</url>
  </required_header>
  <id_info>
    <org_study_id>H-16015331</org_study_id>
    <nct_id>NCT02893215</nct_id>
  </id_info>
  <brief_title>Silent Atrial Fibrillation - Screening of High-risk Groups for Atrial Fibrillation (The Silence Study)</brief_title>
  <official_title>Silent Atrial Fibrillation - Screening of High-risk Groups for Atrial Fibrillation (The Silence Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of the present study is to screen high-risk type 2 diabetes patients and
      heart failure patients without any history of atrial fibrillation (AF), ongoing oral
      anticoagulation (OAC) treatment, implanted device or recent stroke/Transient Ischemic Attack
      (TIA), for silent AF.

      Moreover, we aim to establish the prevalence of two or more risk factors for stroke in
      patients with heart failure and diabetes mellitus type 2 (DM2) with the aim of assessing the
      feasibility for this group to undergo AF screening.

      Overall, the aim of the study is to prevent stroke in high-risk patients groups through
      identification of silent (asymptomatic) atrial fibrillation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The number of screened patients with respectively heart failure and type 2 diabetes with a
      risk score (Congestive Heart Failure, Hypertension, Aged 75 years or older, Diabetes, Stroke
      / transient cerebral ischemia, Vascular disease, Aged 65 years or older and Sex category
      (CHADSVASc)) of two or more, the number of these patients excluded due to AF or ongoing AF,
      the number of eligible patients not included for other reasons, and, finally, number of
      included patients will be listed.

      Patients eligible for screening will be supplied with a hand-held ECG-recorder developed by
      Zenicor Medical Systems (www.zenicor.com) and will transmit recordings 4 times daily
      (morning, midday, evening -at meals - and before bedtime) and in case of symptoms, for 14
      days.

      The transmitted ECGs will be digitally stored, analyzed and screened for AF. All AF episodes
      will recorded and the day and time of the arrhythmia will be registered.

      Eligible patients will be given brief oral and the more thorough written patient information
      about the study, and offered an appointment for the first meeting, which will happen in the
      Cardiological out-patient clinic in Copenhagen University Hospital (Hvidovre) with a member
      of the project group. During the first meeting, the patient will get more information about
      the study and has the possibility to ask questions. If the patient wants to bring a relative
      or friend already at this meeting, this can be arranged. If the patient meets the criteria
      and is interested in participation he/she will be invited to participation in the study. The
      patient gets the rest of the information material, i.e. written informed consent declaration,
      and is given a period for questioning and consideration of participation for at least three
      days. If the patient wants another visit for further information and possibly with
      participation of a relative or friend, such a visit is scheduled, and the patient can be
      included at this visit, and written informed consent declaration can be given to the project
      group member.

      Heart failure patients will have a standardized echocardiography and diabetes patients will
      have supplementary registration of HbA1c, and latest blood glucose value. The latest level of
      creatinine and creatinine clearance will be registered for all patients (DM2 and congestive
      heart failure (CHF)).

      Every patient is given a Study identification (ID) number and there will be a key file
      linking this number and the patient ID; thus, the dataset is anonymized.

      All ECG's will be analyzed using a soft ware based algorithm which has been developed in
      order to exclude normal recordings (sinus rhythm without irregularities).

      Patients with newly detected AF will be referred to the local cardiology out-patient clinic
      or if present OAC clinic for treatment according to established guidelines including OAC
      treatment. Here the patients will be informed about the options of OAC treatment, the reasons
      why we want to offer it, including the risk of developing cerebral ischemic stroke,
      precautions with this treatment and the risks connected to OAC treatment. The treatment with
      OAC is not a part of the screening study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Number of participants with silent atrial fibrillation as assessed by handheld ECG measurements in high-risk heart failure patients.</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with silent atrial fibrillation as assessed by handheld ECG measurements in high-risk type 2 diabetes patients.</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with supraventricular ectopic activity.</measure>
    <time_frame>14 days</time_frame>
    <description>Supraventricular ectopic activity defined as three supraventricular premature beats or more as assessed by handheld ECG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with micro-atrial fibrillation.</measure>
    <time_frame>14 days</time_frame>
    <description>Micro-atrial fibrillation defined as atrial fibrillation shorter than 30 seconds or atrial runs longer than five supraventricular premature beats in a run as assessed by handheld ECG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with high risk of stroke in a heart failure population.</measure>
    <time_frame>2 years</time_frame>
    <description>High risk patients defined as patients aged 65 years or older and at least one additional risk score point without known atrial fibrillation or ongoing oral anticoagulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with high risk of stroke in a type 2 diabetes population.</measure>
    <time_frame>2 years</time_frame>
    <description>High risk patients defined as patients aged 65 years or older and at least one additional risk score point without known atrial fibrillation or ongoing oral anticoagulation.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1622</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Heart failure</arm_group_label>
    <description>Screening for silent AF with Zenicor thumb-ECG: Patients older than 65 years, diagnosed with heart failure, without any history of atrial fibrillation, ongoing OAC treatment, implanted device or recent stroke/TIA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetes mellitus II</arm_group_label>
    <description>Screening for silent AF with Zenicor thumb-ECG: Patients older than 65 years, diagnosed with diabetes mellitus II, without any history of atrial fibrillation, ongoing OAC treatment, implanted device or recent stroke/TIA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Screening for silent AF with Zenicor thumb-ECG</intervention_name>
    <description>Each patient has a device for 14 days, which monitorizes their heart rhythm. They send the ecg four times daily.</description>
    <arm_group_label>Heart failure</arm_group_label>
    <arm_group_label>Diabetes mellitus II</arm_group_label>
    <other_name>Zenicor Medical Systems</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with congestive heart failure and without any history of atrial fibrillation,
        ongoing OAC treatment, implanted device or recent stroke/TIA

        Patients with DM-II and without any history of atrial fibrillation, ongoing OAC treatment,
        implanted device or recent stroke/TIA
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Systolic Congestive Heart Failure diagnosed by echocardiography showing a left
             ventricular ejection fraction (LVEF) ≤ 40%.

          -  Diagnosed Diabetes Mellitus type II.

          -  Age 65 years or older

          -  CHADS-Vasc (Risk score) 2 or higher

        Exclusion Criteria:

          -  Previous history of AF

          -  Ongoing OAC treatment

          -  Implanted device

          -  Recent stroke/TIA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrik Dixen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hvidovre University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ulrik Dixen, MD</last_name>
    <phone>+4538621050</phone>
    <email>ulrik.dixen@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valborg Heinesen, MD</last_name>
    <email>valborgheinesen@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Cardiology, Krankenhaus der Elisabethinen</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helmut Pürerfellner, Prof., Dr.</last_name>
      <email>Helmut.Puererfellner@elisabethinen.or.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kepler Universitätsklinikum GmbH</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clemens Steinwender, MD</last_name>
      <email>clemens.steinwender@akh.linz.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brüder Linz</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Clodi, MD, Prof.</last_name>
      <email>martin.clodi@clodi.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hvidovre University Hospital, Department of cardiology</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrik Dixen, MD</last_name>
      <phone>+4538621050</phone>
      <email>ulrik.dixen@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Valborg Heinesen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annam P. Sheikh, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie B. Jensen, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bjurholms Hälsocentral</name>
      <address>
        <city>Bjurholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Grytnäs Hälsocentral</name>
      <address>
        <city>Kalix</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Karolinske Institute, Department of Cardiology, Danderyd Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ålidhems Hälsocentral</name>
      <address>
        <city>Umea</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vindelns Hälsocentral</name>
      <address>
        <city>Vindeln</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Denmark</country>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation. Med Clin North Am. 2008 Jan;92(1):17-40, ix. Review.</citation>
    <PMID>18060995</PMID>
  </reference>
  <reference>
    <citation>Qvist JF, Sørensen PH, Dixen U. Hospitalisation patterns change over time in patients with atrial fibrillation. Dan Med J. 2014 Jan;61(1):A4765.</citation>
    <PMID>24393590</PMID>
  </reference>
  <reference>
    <citation>Friberg L, Bergfeldt L. Atrial fibrillation prevalence revisited. J Intern Med. 2013 Nov;274(5):461-8. doi: 10.1111/joim.12114. Epub 2013 Aug 7.</citation>
    <PMID>23879838</PMID>
  </reference>
  <reference>
    <citation>Svennberg E, Engdahl J, Al-Khalili F, Friberg L, Frykman V, Rosenqvist M. Mass Screening for Untreated Atrial Fibrillation: The STROKESTOP Study. Circulation. 2015 Jun 23;131(25):2176-84. doi: 10.1161/CIRCULATIONAHA.114.014343. Epub 2015 Apr 24.</citation>
    <PMID>25910800</PMID>
  </reference>
  <reference>
    <citation>Flegel KM, Shipley MJ, Rose G. Risk of stroke in non-rheumatic atrial fibrillation. Lancet. 1987 Mar 7;1(8532):526-9. Erratum in: Lancet 1987 Apr 11;1(8537):878.</citation>
    <PMID>2881082</PMID>
  </reference>
  <reference>
    <citation>Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology. 1978 Oct;28(10):973-7.</citation>
    <PMID>570666</PMID>
  </reference>
  <reference>
    <citation>Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J. 2010 Apr;31(8):967-75. doi: 10.1093/eurheartj/ehn599. Epub 2009 Jan 27.</citation>
    <PMID>19176537</PMID>
  </reference>
  <reference>
    <citation>Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol. 2000 Jan;35(1):183-7.</citation>
    <PMID>10636278</PMID>
  </reference>
  <reference>
    <citation>Savelieva I, Camm AJ. Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. J Interv Card Electrophysiol. 2000 Jun;4(2):369-82. Review.</citation>
    <PMID>10936003</PMID>
  </reference>
  <reference>
    <citation>Rizos T, Wagner A, Jenetzky E, Ringleb PA, Becker R, Hacke W, Veltkamp R. Paroxysmal atrial fibrillation is more prevalent than persistent atrial fibrillation in acute stroke and transient ischemic attack patients. Cerebrovasc Dis. 2011;32(3):276-82. doi: 10.1159/000330348. Epub 2011 Aug 31.</citation>
    <PMID>21893980</PMID>
  </reference>
  <reference>
    <citation>Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, Yang S, Bailleul C, Morillo CA, Carlson M, Themeles E, Kaufman ES, Hohnloser SH; ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012 Jan 12;366(2):120-9. doi: 10.1056/NEJMoa1105575. Erratum in: N Engl J Med. 2016 Mar 10;374(10):998.</citation>
    <PMID>22236222</PMID>
  </reference>
  <reference>
    <citation>Glotzer TV, Hellkamp AS, Zimmerman J, Sweeney MO, Yee R, Marinchak R, Cook J, Paraschos A, Love J, Radoslovich G, Lee KL, Lamas GA; MOST Investigators. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation. 2003 Apr 1;107(12):1614-9. Epub 2003 Mar 24.</citation>
    <PMID>12668495</PMID>
  </reference>
  <reference>
    <citation>Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001 Jun 13;285(22):2864-70.</citation>
    <PMID>11401607</PMID>
  </reference>
  <reference>
    <citation>Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010 Feb;137(2):263-72. doi: 10.1378/chest.09-1584. Epub 2009 Sep 17.</citation>
    <PMID>19762550</PMID>
  </reference>
  <reference>
    <citation>Indredavik B, Rohweder G, Lydersen S. Frequency and effect of optimal anticoagulation before onset of ischaemic stroke in patients with known atrial fibrillation. J Intern Med. 2005 Aug;258(2):133-44.</citation>
    <PMID>16018790</PMID>
  </reference>
  <reference>
    <citation>Saxena R, Lewis S, Berge E, Sandercock PA, Koudstaal PJ. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial. Stroke. 2001 Oct;32(10):2333-7.</citation>
    <PMID>11588322</PMID>
  </reference>
  <reference>
    <citation>Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R, Carolei A. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005 Jun;36(6):1115-9. Epub 2005 May 5.</citation>
    <PMID>15879330</PMID>
  </reference>
  <reference>
    <citation>Marfella R, Sasso FC, Siniscalchi M, Cirillo M, Paolisso P, Sardu C, Barbieri M, Rizzo MR, Mauro C, Paolisso G. Brief episodes of silent atrial fibrillation predict clinical vascular brain disease in type 2 diabetic patients. J Am Coll Cardiol. 2013 Aug 6;62(6):525-30. doi: 10.1016/j.jacc.2013.02.091. Epub 2013 May 15.</citation>
    <PMID>23684685</PMID>
  </reference>
  <reference>
    <citation>Hendrikx T, Hörnsten R, Rosenqvist M, Sandström H. Screening for atrial fibrillation with baseline and intermittent ECG recording in an out-of-hospital population. BMC Cardiovasc Disord. 2013 Jun 10;13:41. doi: 10.1186/1471-2261-13-41.</citation>
    <PMID>23758799</PMID>
  </reference>
  <reference>
    <citation>Hendrikx T, Rosenqvist M, Sandström H, Persson M, Hörnsten R. [Identification of paroxysmal, transient arrhythmias: Intermittent registration more efficient than the 24-hour Holter monitoring]. Lakartidningen. 2015 Jan 6;112. pii: C6SE. Swedish.</citation>
    <PMID>25584602</PMID>
  </reference>
  <reference>
    <citation>Rizzo MR, Sasso FC, Marfella R, Siniscalchi M, Paolisso P, Carbonara O, Capoluongo MC, Lascar N, Pace C, Sardu C, Passavanti B, Barbieri M, Mauro C, Paolisso G. Autonomic dysfunction is associated with brief episodes of atrial fibrillation in type 2 diabetes. J Diabetes Complications. 2015 Jan-Feb;29(1):88-92. doi: 10.1016/j.jdiacomp.2014.09.002. Epub 2014 Sep 16.</citation>
    <PMID>25266244</PMID>
  </reference>
  <reference>
    <citation>Stamboul K, Zeller M, Fauchier L, Gudjoncik A, Buffet P, Garnier F, Guenancia C, Lorgis L, Beer JC, Touzery C, Cottin Y. Incidence and prognostic significance of silent atrial fibrillation in acute myocardial infarction. Int J Cardiol. 2014 Jul 1;174(3):611-7. doi: 10.1016/j.ijcard.2014.04.158. Epub 2014 Apr 22.</citation>
    <PMID>24801093</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2016</study_first_submitted>
  <study_first_submitted_qc>September 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2016</study_first_posted>
  <last_update_submitted>November 2, 2016</last_update_submitted>
  <last_update_submitted_qc>November 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Valborg Heinesen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The ethical approval do not allow us to share individualised data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

